Evidence map›Paper›PMID 34415239›Full record

ArticleAging2021

Identification of effective natural PIK3CA H1047R inhibitors by computational study.

Naimeng Liu, Xinhui Wang, Xuan Li, Xiaye Lv, Haoqun Xie, Zhen Guo, Jing Wang, Gaojing Dou, Ye Du, Dong Song

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Naimeng LiuDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Xinhui WangDepartment of Oncology, First People's Hospital of Xinxiang, Xinxiang, China.
Xuan LiDepartment of Obstetrics and Gynecology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Xiaye LvDepartment of Hematology, Honghui Hospital, Xi'an Jiao Tong University, Xi'an, China.
Haoqun XieClinical College, Jilin University, Changchun, China.
Zhen GuoClinical College, Jilin University, Changchun, China.
Jing WangClinical College, Jilin University, Changchun, China.
Gaojing DouDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Ye DuDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Dong SongDepartment of Breast Surgery, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CNAir Force Medical University · CNXi'an Honghui Hospital · CNXinxiang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with a poor prognosis and a high recurrence rate.

Indexed as

Binding SitesClass I Phosphatidylinositol 3-KinasesComputational BiologyDrug Screening Assays, AntitumorEnzyme InhibitorsFemaleHumansLigandsModels, MolecularMutation, MissensePhenylurea CompoundsPyrimidinesSignal TransductionTriple Negative Breast NeoplasmsWortmanninClass I Phosphatidylinositol 3-KinasesEnzyme InhibitorsLigandsPhenylurea CompoundsPIK3CA protein, humanPKI 402PyrimidinesWortmannindrug developmentPIK3CA H1047Rtargeted therapyTNBCvirtual screening

Identifiers

PMID34415239
PMCPMC8436935
OpenAlexW3194085254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.